Descriptive study of severe hospitalized cases of laboratory-confirmed influenza during five epidemic seasons (2010–2015)

dc.contributor.authorTorner Gràcia, Núria
dc.contributor.authorMartínez, Ana
dc.contributor.authorBasile, Luca
dc.contributor.authorMosquera, Maria Mar
dc.contributor.authorAntón, Andrés
dc.contributor.authorRius, Cristina
dc.contributor.authorSala Farré, Maria Rosa
dc.contributor.authorMinguell, Sofia
dc.contributor.authorPlasencia, Elsa
dc.contributor.authorCarol, Mónica
dc.contributor.authorGodoy i García, Pere
dc.contributor.authorFollia, Núria
dc.contributor.authorBarrabeig i Fabregat, Irene
dc.contributor.authorMarcos, Ma. Angeles
dc.contributor.authorPumarola Suñé, Tomàs
dc.contributor.authorJané, Mireia
dc.date.accessioned2018-06-18T10:51:02Z
dc.date.available2018-06-18T10:51:02Z
dc.date.issued2018-04-04
dc.description.abstractObjective: The Plan of Information on Acute Respiratory Infections in Catalonia (PIDIRAC) included the surveillance of severe hospitalized cases of laboratory-confrmed infuenza (SHCLCI) in 2009. The objective of this study was to determine the clinical, epidemiological and virological features of SHCLCI recorded in 12 sentinel hospitals during fve infuenza seasons. Results: From a sample of SHCLCI recorded during the 5 infuenza epidemics seasons from 2010–2011 to 2014–2015, Cases were confrmed by PCR and/or viral isolation in cell cultures from respiratory samples. A total of 1400 SHCLCI were recorded, 33% required ICU admission and 12% died. The median age of cases was 61 years (range 0–101 years); 70.5% were unvaccinated; 80.4% received antiviral treatment (in 79.6 and 24% of cases within 48 h after hospital admission and the onset of symptoms, respectively); infuenza virus A [37.9% A (H1N1)pdm09, 29.3% A (H3N2)] was identifed in 87.7% of cases. Surveillance of SHCLCI provides an estimate of the severity of seasonal infuenza epidemics and the identifcation and characterization of at-risk groups in order to facilitate preventive measures such as vaccination and early antiviral treatment.ca
dc.format.extent6 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec680564
dc.identifier.issn1756-0500
dc.identifier.pmid29655370
dc.identifier.urihttps://hdl.handle.net/2445/123042
dc.language.isoengca
dc.publisherBioMed Centralca
dc.relation.isformatofReproducció digital del document publicat a: https://doi.org/10.1186/s13104-018-3349-y
dc.relation.ispartofBMC Research notes, 2018, 11:244
dc.relation.urihttps://doi.org/10.1186/s13104-018-3349-y
dc.rightscc by (c) Torner Gràcia, Núria et al., 2018
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationGripcat
dc.subject.classificationEpidemiologiacat
dc.subject.classificationVacunes
dc.subject.otherInfluenzaeng
dc.subject.otherEpidemiologyeng
dc.subject.otherVaccines
dc.titleDescriptive study of severe hospitalized cases of laboratory-confirmed influenza during five epidemic seasons (2010–2015)ca
dc.typeinfo:eu-repo/semantics/articleca
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
680564.pdf
Mida:
577.39 KB
Format:
Adobe Portable Document Format
Descripció: